Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
about
sameAs
Type 2 Diabetes and ADP Receptor Blocker TherapyPharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Anti-platelet therapy: ADP receptor antagonists.Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit heartsEfficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.P2Y12 platelet inhibition in clinical practice.Emerging antiplatelet agents, differential pharmacology, and clinical utility.Evolving role of platelet function testing in coronary artery interventions.Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects.
P2860
Q26772996-AE10F4ED-02A3-47CC-BBDB-EA86FBE3B06FQ33685876-59E4A70A-EB39-4DF2-84B4-4804B9D05311Q33881728-9D8B8EE8-2261-4D9E-87F4-826B31F77A24Q33902628-87DBD5B7-02C0-4C2D-AEB4-B7DD54161FA1Q35176063-D1EFBE38-1238-4E0B-9AD2-EC59F14EA62FQ35278165-FBB72035-7F74-4BE2-BEC0-21845B5DDD87Q36763104-370C0462-3D80-4B8C-8D3D-E51418E9EEC3Q36973414-21EBD6F8-3446-49C0-B5A3-88F8BABDC2F1Q37969927-0A905C97-AF7C-4B52-AA76-32B3A7BEBAAFQ37979178-2FB519F7-39CC-46D1-A377-BCA72F402507Q37988850-B577DAA6-361B-489A-AF86-493E4D97E169Q38037672-14C4AC2A-8D95-4D6D-ABDC-8CAFE4F01E06Q42542451-C0E68BEB-ACFD-487B-BA86-737DCA0FB153
P2860
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Open multicentre study of the ...... with acute coronary syndromes
@ast
Open multicentre study of the ...... with acute coronary syndromes
@en
Open multicentre study of the ...... with acute coronary syndromes
@nl
type
label
Open multicentre study of the ...... with acute coronary syndromes
@ast
Open multicentre study of the ...... with acute coronary syndromes
@en
Open multicentre study of the ...... with acute coronary syndromes
@nl
prefLabel
Open multicentre study of the ...... with acute coronary syndromes
@ast
Open multicentre study of the ...... with acute coronary syndromes
@en
Open multicentre study of the ...... with acute coronary syndromes
@nl
P2093
P1476
Open multicentre study of the ...... with acute coronary syndromes
@en
P2093
K G Oldroyd
R F Storey
R G Wilcox
P407
P577
2001-03-01T00:00:00Z